Bridge Biotherapeutics (Korea) Top Management

288330 Stock  KRW 3,455  430.00  14.21%   
Bridge Biotherapeutics employs about 4 people. The company is managed by 4 executives with a total tenure of roughly 10 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Bridge Biotherapeutics' management performance can provide insight into the company performance.
Taeksang Park  Insider
VP CFO
Gwanghee Lee  Insider
VP Director
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bridge Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Bridge Biotherapeutics Management Team Effectiveness

Bridge Biotherapeutics' management efficiency ratios could be used to measure how well Bridge Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Bridge Biotherapeutics Workforce Comparison

Bridge Biotherapeutics is number one stock in number of employees category among its peers. The total workforce of Biotechnology & Medical Research industry is presently estimated at about 14.0. Bridge Biotherapeutics totals roughly 4.0 in number of employees claiming about 29% of stocks in Biotechnology & Medical Research industry.

Bridge Biotherapeutics Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Bridge Biotherapeutics Price Series Summation is a cross summation of Bridge Biotherapeutics price series and its benchmark/peer.

Bridge Biotherapeutics Notable Stakeholders

A Bridge Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bridge Biotherapeutics often face trade-offs trying to please all of them. Bridge Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bridge Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About Bridge Biotherapeutics Management Performance

The success or failure of an entity such as Bridge Biotherapeutics often depends on how effective the management is. Bridge Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bridge management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bridge management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. The company was founded in 2015 and is headquartered in Seongnam, Korea. BRIDGE BIOTHERAPEUTICS is traded on Korean Securities Dealers Automated Quotations in South Korea.
Please note, the presentation of Bridge Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bridge Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bridge Biotherapeutics' management manipulating its earnings.

Bridge Biotherapeutics Workforce Analysis

Traditionally, organizations such as Bridge Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bridge Biotherapeutics within its industry.

Bridge Biotherapeutics Manpower Efficiency

Return on Bridge Biotherapeutics Manpower

Revenue Per Employee481M
Revenue Per Executive481M
Net Loss Per Employee6.6B
Net Loss Per Executive6.6B

Complementary Tools for Bridge Stock analysis

When running Bridge Biotherapeutics' price analysis, check to measure Bridge Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bridge Biotherapeutics is operating at the current time. Most of Bridge Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bridge Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bridge Biotherapeutics' price. Additionally, you may evaluate how the addition of Bridge Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing